

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

1 INTRODUCTION

The DRG® CA 125 Enzyme Immunoassay Kit provides materials for the quantitative determination of the cancer associated antigen CA 125 in human serum and plasma.

This assay is intended for in vitro use only.

The DRG® CA 125 ELISA is an assay for the detection of OC 125 reactive determinants on a heterogeneous, high-molecular-weight (200 - 1,000 kilodalton) glycoprotein in serum. This glycoprotein was originally defined by the OC 125 monoclonal antibody established by Bast et al. (2)

The DRG® CA125 ELISA uses the M11 and OC 125 mouse monoclonal antibodies as capture antibody.

OC 125 reactive determinants can be found in a high percentage of non-mucinous epithelial ovarian tumors (4) and are found in the serum of women bearing such tumors (5,6).

CA 125 values are increased in most patients with active epithelial ovarian cancer, including those with stage I disease. Elevated CA 125 values are also found in 1-2% of healthy individuals and may be elevated in diseases other than ovarian carcinoma, including both benign and malignant disorders (5,6,12-16).

In women with primary epithelial ovarian carcinoma who had undergone first-line therapy followed by a diagnostic second-look procedures, a CA 125 assay value greater than or equal to 35 U/mL was found to be indicative of the presence of residual tumor (9-11). Assuming the physician cannot identify alternative causes for an elevated CA 125 value, a CA 125 assay value determined to be greater than or equal to 35 U/mL provides substantial evidence that residual tumor is present.

A CA 125 value below 35 U/mL does not indicate the absence of residual ovarian cancer because patients with histopathologic evidence of ovarian carcinoma may have CA 125 assay values within the range of healthy individuals (5,17-21,23,24).

It is recommended that the DRG® CA 125 ELISA be used by or under the order of a physician trained and experienced in the management of gynecologic cancers (29).

2 PRINCIPLE OF THE TEST

The DRG® CA 125 ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a monoclonal antibody directed towards a unique antigenic site on a CA 125 molecule.

An aliquot of patient sample containing endogenous CA 125 is incubated in the coated well with enzyme conjugate, which is an anti-CA 125 monoclonal antibody conjugated with horseradish peroxidase. After incubation the unbound conjugate is washed off. The amount of bound peroxidase is proportional to the concentration of CA 125 in the sample. Having added the substrate solution, the intensity of colour developed is proportional to the concentration of CA 125 in the patient sample.

3 PRECAUTIONS

- This kit is for in vitro use only. In the United States it is intended for Research Use Only.
- For information on hazardous substances included in the kit please refer to Material Safety Data Sheets.
- All reagents of this test kit which contain human serum or plasma have been tested and confirmed negative for HIV I/II, HBsAg and HCV by FDA approved procedures. All reagents, however, should be treated as potential biohazards in use and for disposal.
- Avoid contact with Stop Solution containing 0.5 M H₂SO₄. It may cause skin irritation and burns.
- Never pipet by mouth and avoid contact of reagents and specimens with skin and mucous membranes.
- Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

- Wear disposable latex gloves when handling specimens and reagents. Microbial contamination of reagents or specimens may give false results.
- Handling should be in accordance with the procedures defined by an appropriate national biohazard safety guideline or regulation.
- Do not use reagents beyond expiry date as shown on the kit labels.
- All indicated volumes have to be performed according to the protocol. Optimal test results are only obtained when using calibrated pipettes.
- Do not mix or use components from kits with different lot numbers. It is advised not to exchange wells of different plates even of the same lot. The kits may have been shipped or stored under different conditions and the binding characteristics of the plates may result slightly different.
- Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guideline or regulation.
- Safety Data Sheets for this product are available upon request directly from DRG Instruments GmbH.
- The Safety Data Sheets fit the demands of: EU-Guideline 91/155 EC.

4 KIT COMPONENTS

4.1 Contents of the Kit

1. **Microtiterwells**, 12x8 (break apart) strips, 96 wells
Wells coated with anti-CA 125 mouse monoclonal antibody
2. **Standard (Standard 0-5)**, 6 vials, 1 ml, ready to use
0, 15, 30, 80, 200, 500 U/ml
3. **Control**, 1 vial (lyoph.), 0.5 ml
see „Reagent Preparation“
Control values and ranges please refer to vial label or QC-Datasheet
4. **Enzyme Conjugate 10X concentrate**, 1 vial, 0.75 ml,
anti-CA125 antibody (mouse monoclonal) conjugated to horseradish peroxidase
see „Preparation of Reagents“
5. **Conjugate Diluent**, 1 vial, 7 ml, ready to use
6. **Substrate Solution**, 1 vial, 14 ml, ready to use
TMB
7. **Stop Solution**, 1 vial, 14 ml, ready to use
contains 0.5M H₂SO₄
Avoid contact with the stop solution. It may cause skin irritations and burns.
8. **Wash Solution**, 1 vial, 30 ml (40X concentrated)
see „Preparation of Reagents“

Note: Additional *Standard 0* for sample dilution is available on request.

4.1.1 Equipment and material required but not provided

- A microtiterplate calibrated reader (450±10 nm)(e.g. the DRG Instruments Microtiterplate Reader).
- Calibrated variable precision micropipettes.
- Absorbent paper.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

– Aqua dest.

4.2 Storage and stability of the Kit

When stored at 2-8°C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date. All opened reagents must be stored at 2-8°C. Microtiter wells must be stored at 2-8°C. Once the foilbag has been opened, care should be taken to close it tightly again.

4.3 Preparation of Reagents

Allow all reagents and required number of strips to reach room temperature prior to use.

Control

Reconstitute the lyophilized content with 0.5 ml Aqua dest. and let stand for 10 minutes in minimum. Mix the control several times before use.

Note: The reconstituted control should be apportioned and stored at –20°C.

Wash Solution

Dilute 30 ml of concentrated Wash Solution with 1170 ml deionized water to a final volume of 1200 ml.

The diluted Wash Solution is stable for 2 weeks at room temperature.

Enzyme Conjugate

Dilute Enzyme Conjugate concentrate 1:10 in Conjugate Diluent.

Stability of the prepared Enzyme-Conjugate : 1 weeks at 2–8°C in a sealed container.

Example: Dilute 700 µl of Enzyme Conjugate with 6.3 ml of Conjugate Diluent. If the whole plate is used, dilute 600 µl Enzyme Conjugate with 5.40 ml Conjugate Diluent to a total volume of 6 ml.

If the whole plate is not used at once prepare the required quantity of Enzyme Conjugate by mixing 50 µL of Enzyme Conjugate 10X conc. with 0.45 mL of Conjugate Diluent per strip (see table below):

No. of strips	Enzyme Conjugate 10X conc. (µl)	Conjugate Diluent (ml)
1	50	0.45
2	100	0.90
3	150	1.35
4	200	1.80
5	250	2.25
6	300	2.70
7	350	3.15
8	400	3.60
9	450	4.05
10	500	4.50
11	550	4.95
12	600	5.40

REVISED 11 MAR. 2005**NOT FOR SALE IN THE USA****4.4 Disposal of the Kit**

The disposal of the kit must be made according to the national official regulations. Special information for this product are given in the Material Safety Data Sheets (see chapter 13).

4.5 Damaged Test Kits

In case of any severe damage of the test kit or components, DRG® has to be informed in writing; at the latest, one week after receiving the kit. Severely damaged single components should not be used for a test run. They have to be stored until a final solution has been found. After this, they should be disposed according to the official regulations.

5 SPECIMEN

Serum or Plasma (Heparin- or EDTA-Plasma) can be used in this assay.
Do not use haemolytic, icteric or lipaemic specimens.

5.1 Specimen Collection**Serum:**

Collect blood by venipuncture (e.g Sarstedt Monovette # 02.1388.001), allow to clot, and separate serum by centrifugation at room temperature.

Plasma:

Whole blood should be collected into centrifuge tubes containing anti coagulant and centrifuged immediately after collection.

(E.g for EDTA plasma Sarstedt Monovette – red cap - # 02.166.001; for Heparin plasma Sarstedt Monovette – orange cap - # 02.165.001.)

5.2 Specimen Storage

Specimens should be capped and may be stored for up to 5 days at 2-8°C prior to assaying.

Specimens held for a longer time should be frozen only once at -20°C prior to assay. Thawed samples should be inverted several times prior to testing.

5.3 Specimen Dilution

If in an initial assay, a serum specimen is found to contain more than the highest standard, the specimens can be diluted 10-fold or 100 fold with *Standard 0* and reassayed as described in Assay Procedure.

For the calculation of the concentrations this dilution factor has to be taken into account.

Example:

- a) dilution 1:10: 10 µl Serum + 90 µl Standard 0 (mix thoroughly)
- b) dilution 1:100: 10 µl dilution a) 1:10 + 90 µl Standard 0 (mix thoroughly).

6 TEST PROCEDURE**6.1 General Remarks**

- All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed without foaming.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

- Once the test has been started, all steps should be completed without interruption.
- Use new disposal plastic pipet tips for each standard, control or sample in order to avoid cross-contamination
- Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that all reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for each pipetting step without interruption.
- As a general rule the enzymatic reaction is linearly proportional to time and temperature.

6.2 Assay Procedure

All standards, samples, and controls should be run in duplicate concurrently so that all conditions of testing are the same.

1. Secure the desired number of Microtiterwells in the holder.
2. Dispense **50 µl** of each Standard, controls and samples with new disposable tips into appropriate wells.
3. Dispense **50 µl** freshly diluted Enzyme Conjugate (see „Preparation of Reagents“) into each well.
4. Thoroughly mix for 10 seconds. It is important to have a complete mixing in this step.
5. Incubate for **30 minutes** at room temperature without covering the plate.
6. Briskly shake out the contents of the wells.
Rinse the wells 3 times with diluted Wash Solution (400 µl per well). Strike the wells sharply on absorbent paper to remove residual droplets.
Important note:
The sensitivity and precision of this assay is markedly influenced by the correct performance of the washing procedure!
7. Add **100 µl** of Substrate Solution to each well.
8. Incubate for **30 minutes** at room temperature.
9. Stop the enzymatic reaction by adding **100 µl** of Stop Solution to each well.
10. Read the OD at **450±10 nm** with a microtiterplate reader **within 10 minutes** after adding the Stop Solution.

6.3 Calculation of Results

1. Calculate the average absorbance values for each set of standards, controls and patient samples.
2. Construct a standard curve by plotting the mean absorbance obtained from each standard against its concentration with absorbance value on the vertical(Y) axis and concentration on the horizontal (X) axis.
3. Using the mean absorbance value for each sample determine the corresponding concentration from the standard curve.
4. Automated method: Computer programs using cubic spline, 4 PL (4 Parameter Logistics) or Logit-Log can generally give a good fit.
5. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher than that of the highest standard have to be further diluted. For the calculation of the concentrations this dilution factor has to be taken into account.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

Below is listed a typical example of a standard curve with the CA 125 ELISA.

Standard	Optical Units (450 nm)
Standard 0 (0 U/ml)	0.06
Standard 1 (15 U/ml)	0.12
Standard 2 (30 U/ml)	0.20
Standard 3 (80 U/ml)	0.38
Standard 4 (200 U/ml)	0.88
Standard 5 (500 U/ml)	2.00

7 EXPECTED VALUES

It is strongly recommended that each laboratory should determine its own normal and abnormal values.

5 – 95% Percentile

Healthy individuals

(Men and women): < 29,6 U/ml

This corresponds to the cut-off found in literature with 35 U/ml.

8 ASSAY CHARACTERISTICS

8.1 Assay Dynamic Range

The range of the assay is between 0 – 500 U/ml.

8.2 Specificity of Antibodies (Cross Reactivity)

Sera of healthy individuals did not react with the DRG® CA 125 ELISA.

8.3 Analytical Sensitivity

The analytical sensitivity was calculated from the mean plus two standard deviations of twenty (20) replicate analyses of *Standard 0* and was found to be 3.327 U/ml.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

8.4 Precision

8.4.1 Intra Assay Variation

The within assay variability is shown below:

Sample	n	Mean (U/ml)	CV (%)
1	20	24.99	7.57
2	20	96.70	2.52

8.4.2 Inter Assay Variation

The between assay variability is shown below:

Sample	n	Mean (U/ml)	CV (%)
1	12	28.04	8.26
2	12	99.80	7.12
3	12	43.38	8.25

8.5 Accuracy

8.5.1 Quality Control

It is recommended to use control samples according to state and federal regulations. The use of control samples is advised to assure the day to day validity of results. Use controls at both normal and pathological levels.

The controls and the corresponding results of the QC-Laboratory are stated in the QC certificate added to the kit. The values and ranges stated on the QC sheet always refer to the current kit lot and should be used for direct comparison of the results.

It is also recommended to make use of national or international Quality Assessment programs in order to ensure the accuracy of the results.

Employ appropriate statistical methods for analysing control values and trends. If the results of the assay do not fit to the established acceptable ranges of control materials patient results should be considered invalid.

In this case, please check the following technical areas: Pipetting and timing devices; photometer, expiration dates of reagents, storage and incubation conditions, aspiration and washing methods.

After checking the above mentioned items without finding any error contact your distributor or DRG® directly.

8.5.2 Recovery

Samples have been spiked by adding CA 125 solutions with known concentrations in a 1:1 ratio.

The expected values were calculated by addition of half of the values determined for the undiluted samples and half of the values of the known solutions. The % Recovery has been calculated by multiplication of the ratio of the measurements and the expected values with 100.

REVISED 11 MAR. 2005
NOT FOR SALE IN THE USA

Sample	Added Concentration 1:1 (v/v) (U/ml)	Measured Conc. (U/ml)	Expected Conc. (U/ml)	Recovery (%)
2	0	115,49		
	30	71,73	72,75	98,6
	80	104,95	97,75	107,4
	200	149,06	157,75	94,5
	500	293,64	307,75	95,4
3	0	77,30		
	30	52,93	53,65	98,7
	80	79,36	78,65	100,9
	200	133,35	138,65	96,2
	500	272,27	288,65	94,3

8.5.3 Linearity

Sample	Dilution	Measured Conc. (U/ml)	Expected Conc. (U/ml)	Recovery (%)
1	None	268,42	268,42	
	1:2	131,00	134,21	97,6
	1:4	64,00	67,11	95,4
	1:8	30,84	33,55	91,9
	1:16	15,02	16,78	89,5
2	None	115,49	115,49	
	1:2	51,37	57,75	89,0
	1:4	28,35	28,87	98,2
	1:8	13,96	14,44	96,7
	1:16	7,65	7,22	106,0
3	None	77,30	77,30	
	1:2	39,05	38,65	101,0
	1:4	19,72	19,33	102,0
	1:8	8,35	9,66	86,4
	1:16	4,98	4,83	103,1

9 LIMITATIONS OF USE

9.1 Interfering Substances

Any improper handling of samples or modification of this test might influence the results.

Haemoglobin (up to 4 mg/ml), Bilirubin (up to 0.25 mg/ml) and Triglyceride (up to 30 mg/ml) have no influence on the assay results.

9.2 Drug Interferences

Until today no substances (drugs) are known to us, which have an influence to the measurement of CA 125 in a sample.

REVISED 11 MAR. 2005**NOT FOR SALE IN THE USA****9.3 High-Dose-Hook Effect**

No hook effect was observed in this test.

10 LEGAL ASPECTS**10.1 Reliability of Results**

The test must be performed exactly as per the manufacturer's instructions for use. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially relevant for the use of control reagents. It is important to always include, within the test procedure, a sufficient number of controls for validating the accuracy and precision of the test.

The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within the given assay specifications. In case of any doubt or concern please contact DRG®.

10.2 Therapeutical Consequences

Therapeutical consequences should never be based on laboratory results alone even if all test results are in agreement with the items as stated under point 10.1. Any laboratory result is only a part of the total clinical picture of a patient.

Only in cases where the laboratory results are in acceptable agreement with the overall clinical picture of the patient should therapeutical consequences be derived.

The test result itself should never be the sole determinant for deriving any therapeutical consequences.

10.3 Liability

Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit to another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges invalidate any claim for replacement.

Claims submitted due to customer misinterpretation of laboratory results subject to point 10.2. are also invalid. Regardless, in the event of any claim, the manufacturer's liability is not to exceed the value of the test kit. Any damage caused to the test kit during transportation is not subject to the liability of the manufacturer.

11 REFERENCES

1. van Kamp, G.J., Verstraeten, R.A. and Kenemans, P.: Discordant serum CA 125 values in commercial immunoassays. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 49:99-103, 1993.
2. Bast, R.C., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B., and Knapp, R.C.: Reactivity of a monoclonal antibody with human ovarian carcinoma. *J. Clin. Invest.* 68:1331-1337, 1981.
3. O'Brien, T.J., Raymond, L.M., Bannon, G.A., Ford, D.H., Hardardottir, H., Miller, F.C., and Quirk, J.G.: New monoclonal antibodies identifying the glycoprotein carrying the CA 125 epitope. *Am. J. Obstet. Gynecol.* 165(6 pt 1): 1857-1864, 1991.
4. Kabawat, S. E., Bast, R.C. Jr., Welch, W.R., Knapp, R.C., and Colvin, R.B.: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of ovarian tumors of serous, endometrioid and clear cell types. *Am. J. Clin. Pathol.* 79:98-104, 1983.
5. Bast, R. C. Jr., Klug, T.L., St. John, E., Jenmison, E., Niloff, J. M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, T., Parker, L., Zurawski, V. R. Jr., and Knapp, R. C.: A radioimmunoassay using a monoclonal antibody to monitor to monitor the course of epithelial ovarian cancer. *N. Engl. J. Med.* 309:883-887, 1983.
6. Klug, T. L., Bast, R. C. Jr., Niloff, J. M., Knapp, R. C., and Zurawski, V. R. Jr.: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. *Cancer Res.* 44: 1048-1053, 1984.

REVISED 11 MAR. 2005

NOT FOR SALE IN THE USA

7. Kabawat, S.E., Bast, R.C.Jr., Bhan, A. K., Welch, W. R., Knapp, R.C., and Colvin, R.B.: Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. *Int. J. Gyn. Path.* 2:275-285, 1983.
8. Davis, H.M., Zurawski, V.R. Jr., Bast, R.C. Jr., and Klug, T.L.: Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. *Cancer Res.* 46:6143-6148, 1986.
9. Berek, J.S., Knapp, R.C., Malkasian, G.D., Lavin, P.T., Whitney, C., Niloff, J.M. and Bast, R.C. Jr.: CA 125 serum levels correlated with second-look operations among ovarian cancer patients. *Obstet. Gynecol.* 67:685-689, 1986.
10. Niloff, J.M., Bast, R. C., Jr., Schaetzel, E.M., and Knapp, R.C.: Predictive value of CA 125 antigen levels at second-look procedures in ovarian cancer. *Am. J. Obstet. Gynecol.* 151:981-986, 1985.
11. Atack, D.B., Nisker, J.A., Allen, H.H., Tustanoff, E.R. and Levin, L.: CA 125 surveillance and second-look laparotomy in ovarian carcinoma. *Am. J. Obstet. Gynecol.* 154:287-289, 1986.
12. Niloff, J.M., Klug, T.L., Schaetzel, E., Zurawski, V.R., Jr., Knapp, R.C., and Bast, R.C., Jr.: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. *Am. J. Ob. Gynecol.* 148:1057-1058, 1984.
13. Ruibal, A., Encabo, G., Martinez-Miralles, E., Murci, C., Capdenba B.A. Salgado, and Martinex-Vasquez, J.M.: CA 125 serum levels in non-malignant pathologies. In *Bull. Cancer (Paris)*, Masson Press 71:145-148, 1984.
14. Eerdekens, M.W., Nouwen, E.J., Pollet, D.E., Briers, T.W. and DeBroe, M.E.: Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases. *Clin. Chem.* 31:687-690, 1985.
15. Halila, H., Stenman, U.H. and Seppala, M.: Ovarian cancer antigen CA 125 in pelvic inflammatory disease and pregnancy. *Cancer* 57:1327-1329, 1986.
16. Barbieri, R.L., Niloff, J.M., Bast, R.C., Jr., Schaetzel, E. Kistner, R.W. and Knapp, R.C.: Elevated serum concentrations of CA 125 in patients with advanced endometriosis. *Fert. and Steril.* 45:630-634, 1986.
17. Ricolleau, G., Chatal, J.F, Fumoleau, P., Kremer, M., Douillard, J. Y, and Curtet, C.: Radiomunoassay of the CA 125 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA. *Tumor Biol.* 5:151-159, 1984.
18. Canney, P.A., Moore, M., Wilkinson, P.M., and James, R.D.: Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. *Br. J. Cancer* 50:765-769, 1984.
19. Krebs, H.B., Goplerud, D.R., Kilpatrick, S.J., Myers, M.B. and Hunt, A.: Role of CA 125 as tumor marker in ovarian carcinoma. *Obstet. Gynecol.* 67:473-477, 1986.
20. Kivinen, S., Kuoppala, T., Leppilampi, M., Vuori, J. and Kauppila, A: Tumor-associated antigen CA 125 before and during the treatment of ovarian carcinoma. *Obstet. Gynecol.* 67:468-472, 1986.
21. Einhorn, N., Bast, R.C., Jr., Knapp, R.C., Tjernberg, B. and Zurawski, V.R., Jr.: Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. *Obstet. & Gynecol.* 67:414-416, 1986.
22. Zurawski, V.R., Broderick, S.F., Pickens, P., Knapp, R.C., and Bast, R.C. Jr., Serum CA 125 levels in a Group of Non-hospitalized Women: Relevance for the early detection of Ovarian Cancer. *Obstet. & Gynecol.* 69:606-611, 1987.
23. Niloff, J.M., Knapp, R.C., Schaetzel, E.Reynolds, C., and Bast, R.C., Jr., Jr.: CA 125 levels in obstetric and gynecologic patients. *Obstet. & Gynecol.* 64:703-707, 1984.
24. Bast, R. C., Jr., Klug, T.L., Schaetzel, E., Lavin, O., Niloff, J.M., Greber, T.F., Zurawski, V.R., Jr., and Knapp, R.C.,: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19 9, and CEA. *Am. J. Obstet. Gynecol.* 149:553-559,1984.
25. Muto, M.G., Finkler, N.J., Kassis, A.I., Lepisto, E.M., and Knapp, R.C.: Human antimurine antibody responses in ovarian cancer patients and undergoing radioimmunotherapy with the murine monoclonal antibody OC 125. *Gynecol. Oncol.* 38:244-248, 1990.
26. Turpeinen, U., lehtovirta, P., Alfthan, H., and Stenman, U.: Interface by human antiidiotypic antibodies not neutralized by mouse IgG but removed by chromatography. *Clin. Chem.* 36(7):1333-1338, 1990.

REVISED 11 MAR. 2005**NOT FOR SALE IN THE USA**

27. Reinsberg, J., Heydweiller, A., Wagner, U., Pfell, K., Oehr, P., Krebs, D.: Evidence for interaction of human anti-idiotypic antibodies with the CA 125 determination in a patient after radiommunodetection. Clin. Chem. 36(1):164-167, 1990.
28. Reinsberg, J. and Gast, B.: Human antiidiotypic antibodies against OC 125 strongly interfere with one-step assays of CA 125 employing OC 125 and M II antibodies. Clin. Chem. 40(6):951-952, 1994.
29. Kenemans, P., van Kamp, G.J., Oehr, P. and Verstraeten, R.A.: Heterologous double-determinant immunoradiometric assay Ca 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin. Chem. 39:2509-13, 1993.